Grandmother and granddaughter smiling, representing Boston Scientific's commitment to redefining liver cancer care for patients.

THERASPHERETM Y-90 THERAPY

Liver cancer’s impact and patient testimonials

Elevate awareness in October: Liver Cancer Awareness Month

Liver Cancer Awareness Month is a time to spotlight the urgent need for effective treatment options in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA). Primary liver cancer remains a major global health challenge among the thirteenth most commonly diagnosed cancers1 and the sixth leading cause of cancer death in Europe1.

TheraSphere™ Y-90 with personalised dosimetry supports multimodal treatment strategies for HCC and iCCA patients that prolong survival and expand curative options.

Real stories, real impact:

Martyn's video

Patient testimonial

“SIRT saved my life. Without SIRT, I would be dead by now.”

— Martyn Griffiths

Watch full video
Martyn's video

Interventional Radiologist testimonial

“The downstaging was enough so she could have transplantation.”

— Dr. Yan Rolland

Watch full video
Martyn's video

FELLOW CLINICAL SPECIALIST TESTIMONIAL

“Your disease is not your life. Your life is your life.”

— Holger Sirges

Watch full video
Martyn's video

Patient testimonial

"It has been a procedure that has allowed me to come back to normal life, practicing sport and enjoying my family in a very short time."

— Fernando

Watch full video

Why TheraSphere™ Y-90 Therapy?

When curative options are limited at diagnosis, treatment choice matters.
TheraSphere™ Y-90 Therapy with personalised dosimetry, from bridging and downstaging to lobectomy and segmentectomy, complements systemic options across European centres. 

Europe at a glance: burden and cancer care pathways

Primary liver cancer continues to pose a significant health challenge across Europe. The below statistics underscore the urgent need for prevention, early detection, and timely access to effective treatment options.

+88,871

New Cases per year in Europe.*2

+79,091

Deaths per year in Europe.*2

#13

Most common cancer in Europe.1

#6

Deadliest cancer in Europe.1

TheraSphere™ Y-90 Therapy is used within MDT-led pathways to control disease, preserve liver function, and keep future options open, including the possibility of surgery in selected patients.

Get involved

icon-person-with-headset

Speak with a TheraSphere™ Y-90 expert
Do you have questions? Want to learn more about our products and services?

Contact us
icon-document-with-magnifying-glass

Explore clinical resources
Our interventional oncology portfolio is backed by more than 20 years of clinical research.

Access resources
Icon representing get updates

Stay up-to-date
Receive emails about the latest interventional oncology news, innovations and events.

Stay informed
follow us icon

Join the conversation
Follow us on LinkedIn every Wednesday in October for new testimonials and insights. #LCAM

Follow now

Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

* Aggregated data between HCC and iCCA

1. Preventing liver cancer in the EU: incidence, risk factors, and interventions - European Commission

2. Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.who.int/today, accessed [17 09 2025].